MétaCan
Menu
Back to cohort
Record W4400248956 · doi:10.1038/s44321-024-00094-2

FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer

2024· article· en· W4400248956 on OpenAlexaff
Yifan Tai, Angela Chow, Seo-Young Han, Courtney Coker, Wanchao Ma, Yifan Gu, V. Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova‐Todorova, Anton Safonov, Elaine M. Walsh, Mark E. Robson, Larry Norton, Richard Baer, Taha Merghoub, A. Biswas, Swarnali Acharyya

Bibliographic record

VenueEMBO Molecular Medicine · 2024
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsMcGill University
FundersPershing Square Sohn Cancer Research AllianceMemorial Sloan-Kettering Cancer CenterMETAvivorIrving Medical Center, Columbia UniversityNational Cancer InstituteEmory UniversitySusan G. KomenMonique Weill-Caulier TrustMoffitt Cancer CenterAmerican Cancer SocietyIrma T. Hirschl TrustU.S. Department of Defense
KeywordsCancer researchBreast cancerMedicineCancerPARP inhibitorSynthetic lethalityBiologyInternal medicineDNA repairPoly ADP ribose polymerase

Abstract

fetched live from OpenAlex

Abstract Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA 1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfully targeted in the clinic. Using new PARPi-resistance models of Brca1 - and Bard1 -mutant breast cancer generated in-vivo, we identified FLT1 (VEGFR1) as a driver of resistance. Unlike the known role of VEGF signaling in angiogenesis, we demonstrate a novel, non-canonical role for FLT1 signaling that protects cancer cells from PARPi in-vivo through a combination of cell-intrinsic and cell-extrinsic pathways. We demonstrate that FLT1 blockade suppresses AKT activation, increases tumor infiltration of CD8 + T cells, and causes dramatic regression of PARPi-resistant breast tumors in a T-cell-dependent manner. Moreover, PARPi-resistant tumor cells can be readily re-sensitized to PARPi by targeting Flt1 either genetically ( Flt1 -suppression) or pharmacologically (axitinib). Importantly, a retrospective series of breast cancer patients treated with PARPi demonstrated shorter progression-free survival in cases with FLT1 activation at pre-treatment. Our study therefore identifies FLT1 as a potential therapeutic target in PARPi-resistant, BRCA1/2 -mutant breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.158
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.324
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueEMBO Molecular MedicineSame topicPARP inhibition in cancer therapyFrench-language works237,207